Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population.
Acute coronary syndromes
Coronary artery disease
Older adults
Pharmacotherapy
Revascularization
Journal
Current atherosclerosis reports
ISSN: 1534-6242
Titre abrégé: Curr Atheroscler Rep
Pays: United States
ID NLM: 100897685
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
accepted:
19
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
To provide a comprehensive summary of relevant studies and evidence concerning the utilization of different pharmacotherapeutic and revascularization strategies in managing coronary artery disease and acute coronary syndrome specifically in the older adult population. Approximately 30% to 40% of hospitalized patients with acute coronary syndrome are older adults, among whom the majority of cardiovascular-related deaths occur. When compared to younger patients, these individuals generally experience inferior clinical outcomes. Most clinical trials assessing the efficacy and safety of various therapeutics have primarily enrolled patients under the age of 75, in addition to excluding those with geriatric complexities. In this review, we emphasize the need for a personalized and comprehensive approach to pharmacotherapy for coronary heart disease and acute coronary syndrome in older adults, considering concomitant geriatric syndromes and age-related factors to optimize treatment outcomes while minimizing potential risks and complications. In the realm of clinical practice, cardiovascular and geriatric risks are closely intertwined, with both being significant factors in determining treatments aimed at reducing negative outcomes and attaining health conditions most valued by older adults.
Identifiants
pubmed: 38722473
doi: 10.1007/s11883-024-01203-9
pii: 10.1007/s11883-024-01203-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
De Luca L, Marini M, Gonzini L, Boccanelli A, Casella G, Chiarella F, De Servi S, Di Chiara A, Di Pasquale G, Olivari Z, Caretta G, Lenatti L, Gulizia MM, Savonitto S. Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(12):e004202.
doi: 10.1161/JAHA.116.004202
Meid AD, Quinzler R, Freigofas J, Saum KU, Schöttker B, Holleczek B, et al. Medication underuse in aging outpatients with cardiovascular disease: prevalence, determinants, and outcomes in a prospective cohort study. PLoS ONE. 2015;10(8):e0136339.
doi: 10.1371/journal.pone.0136339
Martin RC. Disparities in heart failure management in older adults. Curr Geriatr Rep. 2023;12(1):1–6.
Bendz B, Aaberge L. Acute coronary syndromes in older patients: does older age matter? Lancet. 2020;396(10251):585–7.
doi: 10.1016/S0140-6736(20)31317-9
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9-119.
doi: 10.1161/CIR.0000000000001168
Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation. 2023;147(3):e32-62.
doi: 10.1161/CIR.0000000000001112
Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798–813.
doi: 10.1161/CIRCULATIONAHA.109.913376
Group BMJP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
doi: 10.1136/bmj.324.7329.71
Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.
doi: 10.1136/bmj.308.6921.81
Nguyen TNM, Sha S, Chen LJ, Holleczek B, Brenner H, Schöttker B. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. Aliment Pharmacol Ther. 2022;56(2):251–62.
doi: 10.1111/apt.17050
Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–9.
doi: 10.1016/S0140-6736(17)30770-5
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e18-114.
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.
doi: 10.1056/NEJMoa1908973
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;ehad191.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
doi: 10.1056/NEJMoa0706482
Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes. Ann Intern Med. 2020;173(6):436–44.
doi: 10.7326/M20-1806
Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018;137(23):2435–45.
doi: 10.1161/CIRCULATIONAHA.117.032180
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.
doi: 10.1056/NEJMoa0904327
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.
doi: 10.1056/NEJMoa1500857
Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome. Circulation. 2020;142(18):1700–8.
doi: 10.1161/CIRCULATIONAHA.120.050645
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–81.
doi: 10.1016/S0140-6736(20)30325-1
Montalto C, Morici N, Munafò AR, Mangieri A, Mandurino-Mirizzi A, D’Ascenzo F, et al. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. Eur Heart J - Cardiovasc Pharmacother. 2022;8(1):20–7.
doi: 10.1093/ehjcvp/pvaa101
Crimi G, Morici N, Ferrario M, Ferri LA, Piatti L, Grosseto D, et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc. 2019;8(2):e010956.
doi: 10.1161/JAHA.118.010956
Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–367.
doi: 10.1093/eurheartj/ehaa575
Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–57.
doi: 10.1016/S0140-6736(17)32155-4
Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6(9):e24964.
doi: 10.1371/journal.pone.0024964
Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(1):83–99.
doi: 10.1016/j.jacc.2019.05.016
Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.
doi: 10.1001/archinternmed.2010.271
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13.
doi: 10.1056/NEJMoa1904143
Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583–96.
doi: 10.1161/CIRCULATIONAHA.120.050438
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.
doi: 10.1056/NEJMoa1611594
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.
doi: 10.1056/NEJMoa1708454
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.
doi: 10.1056/NEJMoa1817083
Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. EP Eur. 2020;22(4):538–46.
Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279–89.
Gundersen T, Abrahamsen AM, Kjekshus J, Rønnevik PK. Timolol-related reduction in mortality and reinfarction in patients ages 65–75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation. 1982;66(6):1179–84.
The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The beta-blocker pooling project research group. Eur Heart J. 1988;9(1):8–16.
A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982;247(12):1707–14.
Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, et al. Comparative effectiveness of β-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients. Circ Cardiovasc Qual Outcomes. 2019;12(7):e005103.
doi: 10.1161/CIRCOUTCOMES.118.005103
Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194–9.
doi: 10.1161/01.CIR.0000035653.72855.BF
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.
Gilstrap L, Austin AM, O’Malley AJ, Gladders B, Barnato AE, Tosteson A, et al. Association between beta-blockers and mortality and readmission in older patients with heart failure: an instrumental variable analysis. J Gen Intern Med. 2021;36(8):2361–9.
doi: 10.1007/s11606-021-06901-7
Zullo AR, Lee Y, Daiello LA, Mor V, John Boscardin W, Dore DD, et al. Beta-blocker use in U.S. Nursing home residents after myocardial infarction: a national study. J Am Geriatr Soc. 2017;65(4):754–62.
Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2018;11(4):e004356.
doi: 10.1161/CIRCOUTCOMES.117.004356
Misumida N, Harjai K, Kernis S, Kanei Y. Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A Meta-Analysis J Cardiovasc Pharmacol Ther. 2016;21(3):280–5.
doi: 10.1177/1074248415608011
Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, et al. Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation. 2015;131(25):2194–201.
doi: 10.1161/CIRCULATIONAHA.114.014209
Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;20(354):i4801.
doi: 10.1136/bmj.i4801
Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015;115(11):1529–38.
doi: 10.1016/j.amjcard.2015.02.057
Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.
doi: 10.1001/archinte.166.17.1842
Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9.
doi: 10.1001/jama.2012.12559
Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69(22):2710–20.
doi: 10.1016/j.jacc.2017.03.578
Fukase T, Dohi T, Koike T, Yasuda H, Takeuchi M, Takahashi N, et al. Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention. ESC Heart Fail. 2022;9(1):545–54.
doi: 10.1002/ehf2.13715
Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, et al. Association of β-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern Med. 2017;177(2):254–62.
doi: 10.1001/jamainternmed.2016.7701
Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, et al. Acute coronary care in the elderly. Part I Circulation. 2007;115(19):2549–69.
doi: 10.1161/CIRCULATIONAHA.107.182615
Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013;49(1):1–6.
doi: 10.4068/cmj.2013.49.1.1
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.
Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328–50.
doi: 10.1161/CIRCRESAHA.118.312782
Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.
doi: 10.1016/S0140-6736(18)31942-1
Collaboration CTT (CTT). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.
doi: 10.1016/S0140-6736(16)31357-5
Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.
doi: 10.1093/eurheartj/ehac015
Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–9.
Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A, et al. PCSK9, a promising novel target for age-related cardiovascular dysfunction. JACC Basic Transl Sci. 2023;8(10):1334–53.
doi: 10.1016/j.jacbts.2023.06.005
Stoll F, Eidam A, Michael L, Bauer JM, Haefeli WE. Drug treatment of hypercholesterolemia in older adults: focus on newer agents. Drugs Aging. 2022;39(4):251–6.
doi: 10.1007/s40266-022-00928-z
Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol. 2021;28(8):805–12.
doi: 10.1177/2047487320902750
Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248–58.
doi: 10.1093/eurheartj/ehz809
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.
doi: 10.1056/NEJMoa032292
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–8.
doi: 10.1161/01.CIR.100.23.2312
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.
doi: 10.1016/S0140-6736(09)61913-9
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–34.
Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2(4):274–302.
doi: 10.1016/j.amjopharm.2004.12.005
Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–77.
doi: 10.1016/j.amjopharm.2011.10.004
Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080–7.
doi: 10.1053/j.ajkd.2005.08.018
Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA, Rajan KB, et al. Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: a meta-analysis. Hypertension. 2021;78(3):629–43.
doi: 10.1161/HYPERTENSIONAHA.121.17049
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385(20):1845–55.
doi: 10.1056/NEJMoa2104508
Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040–8.
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–st-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update) [Internet]. [cited 2024 Feb 10]. Available from: https://www.ahajournals.org/doi/epub/10.1161/CIR.0b013e318256f1e0
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.
doi: 10.1056/NEJMoa030207
Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA, et al. Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction. J Am Heart Assoc. 5(1):e002612.
Kalra S. Sodium glucose Co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355–66.
doi: 10.1007/s13300-014-0089-4
Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801.
doi: 10.1016/S0140-6736(22)02074-8
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–68.
doi: 10.1001/jama.2020.1906
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
doi: 10.1056/NEJMoa1911303
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
doi: 10.1056/NEJMoa2022190
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29.
doi: 10.1016/S0140-6736(20)31824-9
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.
doi: 10.1161/CIR.0000000000000456
Van Horn L, Carson JAS, Appel LJ, Burke LE, Economos C, Karmally W, et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016;134(22):e505–29.
Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. BMJ Open Diabetes Res Care. 2020;8(1):e001279.
doi: 10.1136/bmjdrc-2020-001279
McGill JB, Subramanian S. Safety of sodium-glucose Co-transporter 2 inhibitors. Am J Med. 2019;132(10, Supplement):S49-S57.e5.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
doi: 10.1056/NEJMoa1504720
Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study. Diabetes Care. 2020;43(2):468–75.
doi: 10.2337/dc19-1476
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4(4):e143–54.
doi: 10.1016/S2666-7568(23)00032-6
Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146(16):1210–24.
doi: 10.1161/CIRCULATIONAHA.122.061754
Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013. Diabetes Obes Metab. 2016;18(6):607–14.
doi: 10.1111/dom.12658
Baquero GA, Rich MW. Perioperative care in older adults. J Geriatr Cardiol JGC. 2015;12(5):465–9.
Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med. 2016;374(8):728–37.
Gerstein NS, Albrechtsen CL, Mercado N, Cigarroa JE, Schulman PM. A comprehensive update on aspirin management during noncardiac surgery. Anesth Analg. 2020;131(4):1111–23.
doi: 10.1213/ANE.0000000000005064
Banerjee S, Angiolillo DJ, Boden WE, Murphy JG, Khalili H, Hasan AA, et al. Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol. 2017;69(14):1861–70.
doi: 10.1016/j.jacc.2017.02.012
Moster M, Bolliger D. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. Curr Anesthesiol Rep. 2022;12(2):286–96.
doi: 10.1007/s40140-021-00511-z
Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(22):e77-137.
doi: 10.1016/j.jacc.2014.07.944
Durazzo AES, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leão P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004;39(5):967–75.
doi: 10.1016/j.jvs.2004.01.004
Berwanger O, de Barros E Silva PGM, Barbosa RR, Precoma DB, Figueiredo EL, Hajjar LA, et al. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: the Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. Am Heart J. 2017;184:88–96.
Turan A, You J, Shiba A, Kurz A, Saager L, Sessler DI. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg. 2012;114(3):552.
doi: 10.1213/ANE.0b013e318241f6af
Rajani R, Lindblom M, Dixon G, Khawaja MZ, Hildick-Smith D, Holmberg S, et al. Evolving trends in percutaneous coronary intervention. Br J Cardiol. 2011;18(2):73–6.
Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398(10318):2247–57.
doi: 10.1016/S0140-6736(21)02334-5
Stouffer GA, Mott L, Brizolara A, Subbarao V. Left main coronary artery disease in adults younger than 50 years: A comparison with older patients. Catheter Cardiovasc Interv. 2000;51(1):11–7.
doi: 10.1002/1522-726X(200009)51:1<11::AID-CCD3>3.0.CO;2-V
null null, O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4):e362–425.
Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, García EJ, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32(1):51–60.
Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med. 2023;389(10):889–98.
doi: 10.1056/NEJMoa2300468
Gnanenthiran SR, Kritharides L, D’Souza M, Lowe HC, Brieger DB. Revascularisation compared with initial medical therapy for non-ST-elevation acute coronary syndromes in the elderly: a meta-analysis. Heart. 2017;103(24):1962–9.
2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes | circulation [internet]. [cited 2023 Sep 12]. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000134
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndromeestimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.
doi: 10.1001/jama.291.22.2727
Scruth EA, Cheng E, Worrall-Carter L. Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur J Cardiovasc Nurs. 2013;12(4):330–6.
doi: 10.1177/1474515112449412
Fox KAA, FitzGerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425.
doi: 10.1136/bmjopen-2013-004425
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61.
doi: 10.1161/CIRCULATIONAHA.119.040167
Damluji AA, Forman DE, van Diepen S, Alexander KP, Page RL, Hummel SL, et al. Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. Circulation. 2020;141(2):e6-32.
doi: 10.1161/CIR.0000000000000741
Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromesa collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908–17.
doi: 10.1001/jama.293.23.2908
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708–15.
Rosa RD, Morici N, Luca GD, Luca LD, Ferri LA, Piatti L, et al. Association of sex with outcome in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2021;134(9):1135-1141.e1.
doi: 10.1016/j.amjmed.2021.03.025
Sanchis J, Núñez E, Barrabés JA, Marín F, Consuegra-Sánchez L, Ventura S, et al. Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. Eur J Intern Med. 2016;1(35):89–94.
doi: 10.1016/j.ejim.2016.07.003
Hirlekar G, Libungan B, Karlsson T, Bäck M, Herlitz J, Albertsson P. Percutaneous coronary intervention in the very elderly with NSTE-ACS: the randomized 80+ study. Scand Cardiovasc J. 2020;54(5):315–21.
doi: 10.1080/14017431.2020.1781243
Belder A de, Myat A, Blaxill J, Haworth P, O’Kane P, Hatrick R, et al. EuroIntervention. [cited 2023 Sep 12]. Revascularisation or medical therapy in elderly patients with acute anginal syndromes: the RINCAL randomised trial. Available from: https://eurointervention.pcronline.com/article/revascularisation-or-medical-therapy-in-elderly-patients-with-acute-anginal-syndromes-rincal-a-randomised-trial.
Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet. 2016;387(10023):1057–65.
doi: 10.1016/S0140-6736(15)01166-6
Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41–50.
doi: 10.1016/S0140-6736(17)32713-7
Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465–76.
doi: 10.1016/S0140-6736(15)60292-6
Tehrani BN, Damluji AA, Sherwood MW, Rosner C, Truesdell AG, Epps KC, et al. Transradial access in acute myocardial infarction complicated by cardiogenic shock: Stratified analysis by shock severity. Catheter Cardiovasc Interv. 2021;97(7):1354–66.
doi: 10.1002/ccd.29098
Dobaria V, Hadaya J, Sanaiha Y, Aguayo E, Sareh S, Benharash P. The pragmatic impact of frailty on outcomes of coronary artery bypass grafting. Ann Thorac Surg. 2021;112(1):108–15.
doi: 10.1016/j.athoracsur.2020.08.028
Tran DTT, Tu JV, Dupuis J, Bader Eddeen A, Sun LY. Association of frailty and long-term survival in patients undergoing coronary artery bypass grafting. J Am Heart Assoc. 2018;7(15):e009882.
doi: 10.1161/JAHA.118.009882
Kochar A, Deo SV, Charest B, Peterman-Rocha F, Elgudin Y, Chu D, et al. Preoperative frailty and adverse outcomes following coronary artery bypass grafting surgery in US veterans. J Am Geriatr Soc. 2023;71(9):2736–47.
doi: 10.1111/jgs.18390
Alkhouli M, Alqahtani F, Kalra A, Gafoor S, Alhajji M, Alreshidan M, et al. Trends in characteristics and outcomes of hospital inpatients undergoing coronary revascularization in the United States, 2003–2016. JAMA Netw Open. 2020;3(2):e1921326.
doi: 10.1001/jamanetworkopen.2019.21326
ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, Gammie JS. Trends in isolated coronary artery bypass grafting: an analysis of the society of thoracic surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg. 2012;143(2):273–81.
doi: 10.1016/j.jtcvs.2011.10.029
Filsoufi F, Rahmanian PB, Castillo JG, Chikwe J, Silvay G, Adams DH. Results and predictors of early and late outcomes of coronary artery bypass graft surgery in octogenarians. J Cardiothorac Vasc Anesth. 200AD;21(6):784–92.
doi: 10.1053/j.jvca.2007.08.007
Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, et al. Outcomes of coronary artery bypass graft surgery versus drug-eluting stents in older adults. J Am Geriatr Soc. 2017;65(3):625–30.
doi: 10.1111/jgs.14780
Khan MR, Kayani WT, Ahmad W, Manan M, Hira RS, Hamzeh I, et al. Effect of increasing age on percutaneous coronary intervention vs coronary artery bypass grafting in older adults with unprotected left main coronary artery disease: A meta-analysis and meta-regression. Clin Cardiol. 2019;42(11):1071–8.
doi: 10.1002/clc.23253
Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggiani LB, et al. Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: a meta-analysis of 6 randomized trials and 4,686 patients. Am Heart J. 2017;1(190):54–63.
doi: 10.1016/j.ahj.2017.05.005
Whitlock EL, Diaz-Ramirez LG, Smith AK, Boscardin WJ, Covinsky KE, Avidan MS, et al. Association of coronary artery bypass grafting vs percutaneous coronary intervention with memory decline in older adults undergoing coronary revascularization. JAMA. 2021;325(19):1955–64.
doi: 10.1001/jama.2021.5150
O’Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, et al. The society of thoracic surgeons 2018 adult cardiac surgery risk models: part 2—statistical methods and results. Ann Thorac Surg. 2018May 1;105(5):1419–28.
doi: 10.1016/j.athoracsur.2018.03.003
Diegeler A, Börgermann J, Kappert U, Breuer M, Böning A, Ursulescu A, et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med. 2013;368(13):1189–98.
doi: 10.1056/NEJMoa1211666
Olenski AR, Zimerman A, Coussens S, Jena AB. Behavioral heuristics in coronary-artery bypass graft surgery. N Engl J Med. 2020;382(8):778–9.
doi: 10.1056/NEJMc1911289
Böning A, Diegeler A, Hilker M, Zacher M, Reents W, Faerber G, et al. Preoperative atrial fibrillation and outcome in patients undergoing on-pump or off-pump coronary bypass surgery: lessons learned from the GOPCABE trial. Interact Cardiovasc Thorac Surg. 2015;20(1):74–8.
doi: 10.1093/icvts/ivu331
Llorens-Ortega R, Bertran-Noguer C, Juvinyà-Canals D, Garre-Olmo J, Bosch-Farré C. Influence of social determinants of health in the evolution of the quality of life of older adults in Europe: a comparative analysis between men and women. Humanit Soc Sci Commun. 2024;11(1):1–13.
doi: 10.1057/s41599-024-02899-5
Iung B. Interface between valve disease and ischaemic heart disease. Heart Br Card Soc. 2000;84(3):347–52.
doi: 10.1136/heart.84.3.347
Kvidal P, Bergström R, Hörte LG, Ståhle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35(3):747–56.
doi: 10.1016/S0735-1097(99)00584-7
Matta A, Moussallem N. Coronary artery disease is associated with valvular heart disease, but could it Be a predictive factor? Indian Heart J. 2019;71(3):284–7.
doi: 10.1016/j.ihj.2019.07.001
Grubb KJ, Nazif T, Williams MR, George I. Concurrent coronary artery and valvular heart disease – hybrid treatment strategies in 2013. Interv Cardiol Rev. 2013;8(2):127–30.
doi: 10.15420/icr.2013.8.2.127
Brinster DR, Byrne M, Rogers CD, Baim DS, Simon DI, Couper GS, et al. Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease (“hybrid approach”). Am J Cardiol. 2006;98(11):1501–3.
doi: 10.1016/j.amjcard.2006.08.010
Otto CM, Nishimura RA, Bonow RO, Carabello BA, III JPE, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation [internet]. 2021 Feb 2 [cited 2024 Feb 11]; Available from: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000923
Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137(7):563–70.
doi: 10.7326/0003-4819-137-7-200210010-00007
Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137(7):555–62.
doi: 10.7326/0003-4819-137-7-200210010-00006
Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–84.
doi: 10.1053/j.ajkd.2004.11.015
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventiona randomized controlled trial. JAMA. 2002;288(19):2411–20.
doi: 10.1001/jama.288.19.2411
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | NEJM [internet]. [cited 2024 Feb 11]. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa050522
Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome. Circulation. 2015;131(12):1123–49.
doi: 10.1161/CIR.0000000000000183
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet Lond Engl. 2009;373(9678):1849–60.
Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.
Zoungas S, Curtis A, Spark S, Wolfe R, McNeil JJ, Beilin L, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915.
doi: 10.1136/bmjopen-2022-069915